JPRN-UMIN000003741已完成未知
Efficacy and Safety of Valsartan and Aliskiren Combination Therapy in Patients with Diabetic Nephropathy and Hypertension - Valsartan and Aliskiren Combination Therapy
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 80
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 30years-old 至 80years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1)Taking corticosteroid 2)Secondary hypertension or maliganant hypertension 3)Acute myocardial infarction within 24 weeks 4)Stroke within 12 weeks 5)Severe ventricular tachyarrhythmia or advanced AV block 6)Cardiogenic shock 7)Bilateral renal artery stenosis 8)Sever liver dysfunction 9)Severe hematopoietic disorder or carcinoma 10)Type 1 diabetes 11)Taking cyclosporine A 12)Pregnancy 13)Drug allergy 14) not qualified
研究者
相似试验
进行中（未招募）
不适用
Efficacy and safety of a medicine containing the active substance valsartan, or a medicine (fixed-dose combination) containing the two active substances valsartan and hydrochlorothiazide in the treatment of patients with high blood pressure.Patients with mild to moderate arterial hypertension.MedDRA version: 14.1Level: LLTClassification code 10020775Term: Hypertension arterialSystem Organ Class: 10047065 - Vascular disordersMedDRA version: 14.1Level: PTClassification code 10020772Term: HypertensionSystem Organ Class: 10047065 - Vascular disordersEUCTR2012-005129-57-SIKrka, d.d., Novo mesto500
进行中（未招募）
不适用
Efficacy and safety of a medicine containing the active substance valsartan, or a medicine (fixed-dose combination) containing the two active substances valsartan and hydrochlorothiazide in the treatment of patients with high blood pressure.Patients with mild to moderate arterial hypertension.MedDRA version: 14.1Level: LLTClassification code 10020775Term: Hypertension arterialSystem Organ Class: 10047065 - Vascular disordersMedDRA version: 14.1Level: PTClassification code 10020772Term: HypertensionSystem Organ Class: 10047065 - Vascular disordersEUCTR2012-005129-57-CZKRKA CR, s.r.o.500
尚未招募
4 期
TO COMPARE THE SAFETY & EFFICACY OF AZILSARTAN VERSUS OLMESARTAN AS ADD ON THERAPY TO CHLORTHALIDONE IN COEXISTING HYPERTENSION WITH TYPE-2 DIABETES MELLITUS RANDOMISED CONTROLLED TRIACTRI/2020/04/024756DR DEEKSHA SHARMA
已完成
3 期
Clinical Study to Evaluate Efficacy and Safety of Aliskiren (150mg & 300mg) Administered Alone and in Combo With Valsartan (160mg and 320mg) in Patients With High Blood PressureHypertensionNCT00219180Novartis1,797
已完成
不适用
A clinical trial to study the effects of two drugs,Azilsartan and Losartan in patients with high blood pressureCTRI/2020/08/027209PIMS105